SeaStar Medical Completes FDA Enrollment for Pediatric AKI Therapy Study

Event summary

  • SeaStar Medical completed enrollment of 50 patients in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA for QUELIMMUNE therapy in pediatric AKI due to sepsis.
  • Early results from the SAVE Registry, published in Pediatric Nephrology, showed promising safety and efficacy data for QUELIMMUNE.
  • QUELIMMUNE therapy has been adopted by multiple nationally recognized children’s medical centers in the U.S.
  • The NEUTRALIZE-AKI pivotal trial is ongoing, evaluating the safety and efficacy of SCD therapy in adult AKI patients.

The big picture

SeaStar Medical’s completion of the SAVE Registry enrollment marks a critical step in validating QUELIMMUNE’s safety for pediatric AKI patients. The therapy’s potential to address destructive hyperinflammation positions it as a significant innovation in critical care. The ongoing NEUTRALIZE-AKI trial could further expand the market for SCD therapy, addressing a substantial unmet need in adult AKI patients.

What we're watching

Regulatory Compliance
How the FDA’s review of the SAVE Registry data will impact QUELIMMUNE’s market approval and adoption.
Market Expansion
Whether SeaStar Medical can accelerate adoption of QUELIMMUNE in children’s hospitals despite regulatory hurdles.
Clinical Trial Progress
The pace at which the NEUTRALIZE-AKI trial will yield results, potentially expanding SCD therapy to adult AKI patients.

Related topics

Biotechnology